Press Release
<< Back
Verastem to Present at the 2014 ASCO Annual Meeting
Interim data from the ongoing Phase 1/1b trial of lead candidate targeting cancer stem cells, VS-6063 (defactinib), a potent inhibitor of focal adhesion kinase (FAK), in combination with paclitaxel in patients with ovarian cancer will be presented. The study has completed enrollment of 22 patients at three sites in the US. In addition, investigators will present posters on the ongoing registration-directed COMMAND study of VS-6063 for patients with malignant pleural mesothelioma and the ongoing Phase 2 study of VS-6063 for patients with non-small cell lung cancer.
The company is also holding an analyst and investor event on the Sunday
morning of
The details for the poster presentations and events are as follows:
Date & Time:
Poster
Title: COMMAND: A Phase II Randomized, Double-blind,
Placebo-Controlled, Multicenter Study of Defactinib as Maintenance
Therapy in Subjects with Malignant Pleural Mesothelioma which has Not
Progressed on at least 4 Cycles of Pemetrexed/Platinum therapy
Abstract
Number: TPS7611
Session ID: General Poster Session: Lung
Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Location:
S Hall A2
Date & Time:
Poster
Title: A phase 2 study of defactinib (VS-6063), a cancer stem cell
inhibitor that acts through inhibition of focal adhesion kinase (FAK),
in patients (pts) with KRAS-mutant-non-small-cell lung cancer (NSCLC)
Abstract
Number: TPS8126
Session ID: General Poster Session: Lung
Cancer - Non-small Cell Metastatic
Location: S Hall A2
Date & Time:
Poster Title: Phase 1/1b Study of the FAK Inhibitor
Defactinib (VS-6063) in Combination with Weekly Paclitaxel for Advanced
Ovarian Cancer
Abstract Number: 5521
Session ID:
Poster Highlights Session: Gynecologic Cancer
Location:
E354b & E354a
Analyst Breakfast and Webcast
The full invitation can be accessed here. Please RSVP to Verastem@argotpartners.com.
A live, listen-only webcast of the event can be accessed here
five minutes prior to the start of the event. A replay of the webcast
will be archived on the
About VS-6063
VS-6063 (defactinib) is an orally available compound designed to target
cancer stem cells through the potent inhibition of focal adhesion kinase
(FAK). Cancer stem cells are an underlying cause of tumor resistance to
chemotherapy, recurrence and ultimate disease progression. Research by
About COMMAND
COMMAND is a registration-directed, double-blind, placebo-controlled trial of VS-6063 with Progression Free Survival (PFS) and Overall Survival (OS) as the primary endpoints. VS-6063 targets cancer stem cells. Cancer stem cells are an underlying cause of tumor progression and recurrence. The design of COMMAND allows the opportunity to enrich for patients with tumors low in the biomarker, merlin. Preclinical and early clinical research has demonstrated that low merlin levels may be predictive of increased effectiveness of FAK inhibitors such as VS-6063. The COMMAND study stratifies patients to evaluate the effect of VS-6063 in both the overall patient population and the subgroup of patients whose tumors are low in merlin.
COMMAND is expected to enroll approximately 350-400 patients at clinical
sites in 12 countries, including the US,
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, including VS-6063,
or defactinib, and the Company’s FAK inhibition program, the timeline
for clinical development and regulatory approval of the Company’s
compounds, the expected timing for the reporting of data from ongoing
trials, and the structure of the Company’s planned or pending clinical
trials, and potential indications for clinical development. The words
“anticipate,” “appear,” “believe,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include
the risks that the preclinical testing of the Company’s compounds and
preliminary data from clinical trials may not be predictive of the
results or success of ongoing or later clinical trials, that data may
not be available when we expect it to be, that enrollment of clinical
trials may take longer than expected, that the Company will be unable to
successfully complete the clinical development of its compounds,
including VS-6063, that the development of the Company’s compounds will
take longer or cost more than planned, and that the Company’s compounds
will not receive regulatory approval or become commercially successful
products. Other risks and uncertainties include those identified under
the heading “Risk Factors” in the Company’s Annual Report on Form 10-K
for the year ended
Source:
Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com